JPH107541A - Skin lotion - Google Patents
Skin lotionInfo
- Publication number
- JPH107541A JPH107541A JP18132196A JP18132196A JPH107541A JP H107541 A JPH107541 A JP H107541A JP 18132196 A JP18132196 A JP 18132196A JP 18132196 A JP18132196 A JP 18132196A JP H107541 A JPH107541 A JP H107541A
- Authority
- JP
- Japan
- Prior art keywords
- derivatives
- vitamin
- skin
- external preparation
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006210 lotion Substances 0.000 title abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 19
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims abstract description 16
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 16
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 15
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 15
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 13
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 11
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract description 11
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 10
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 10
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 10
- 239000011719 vitamin A Substances 0.000 claims abstract description 10
- 229940045997 vitamin a Drugs 0.000 claims abstract description 10
- 229930003448 Vitamin K Natural products 0.000 claims abstract description 9
- 239000001648 tannin Substances 0.000 claims abstract description 9
- 229920001864 tannin Polymers 0.000 claims abstract description 9
- 235000018553 tannin Nutrition 0.000 claims abstract description 9
- 235000019168 vitamin K Nutrition 0.000 claims abstract description 9
- 239000011712 vitamin K Substances 0.000 claims abstract description 9
- 229940046010 vitamin k Drugs 0.000 claims abstract description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 8
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 8
- 235000021466 carotenoid Nutrition 0.000 claims abstract description 8
- 229930003935 flavonoid Natural products 0.000 claims abstract description 8
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 8
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 8
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 8
- 239000011718 vitamin C Substances 0.000 claims abstract description 8
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 8
- 239000011709 vitamin E Substances 0.000 claims abstract description 8
- 229940046009 vitamin E Drugs 0.000 claims abstract description 8
- 150000003721 vitamin K derivatives Chemical class 0.000 claims abstract description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960002477 riboflavin Drugs 0.000 claims abstract description 7
- 239000002151 riboflavin Substances 0.000 claims abstract description 7
- 235000019192 riboflavin Nutrition 0.000 claims abstract description 7
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 5
- 229960005305 adenosine Drugs 0.000 claims abstract description 5
- 239000002537 cosmetic Substances 0.000 claims abstract description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000001867 cobalamins Chemical class 0.000 claims abstract description 3
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 22
- -1 spiriroxanthin Chemical compound 0.000 claims description 15
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 12
- 229940088594 vitamin Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- 235000010323 ascorbic acid Nutrition 0.000 claims description 8
- 229960005070 ascorbic acid Drugs 0.000 claims description 8
- 239000011668 ascorbic acid Substances 0.000 claims description 8
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 8
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 7
- 150000001747 carotenoids Chemical class 0.000 claims description 7
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 claims description 6
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 claims description 6
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 5
- 235000013793 astaxanthin Nutrition 0.000 claims description 5
- 239000001168 astaxanthin Substances 0.000 claims description 5
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 5
- 229940022405 astaxanthin Drugs 0.000 claims description 5
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 4
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 claims description 4
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 4
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 4
- 235000013734 beta-carotene Nutrition 0.000 claims description 4
- 239000011648 beta-carotene Substances 0.000 claims description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 4
- 229960002747 betacarotene Drugs 0.000 claims description 4
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 claims description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 4
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 claims description 4
- 229940041603 vitamin k 3 Drugs 0.000 claims description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 claims description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 3
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 claims description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims description 3
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 claims description 3
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims description 3
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 3
- 229940087168 alpha tocopherol Drugs 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 229940066595 beta tocopherol Drugs 0.000 claims description 3
- 235000020960 dehydroascorbic acid Nutrition 0.000 claims description 3
- 239000011615 dehydroascorbic acid Substances 0.000 claims description 3
- 235000010389 delta-tocopherol Nutrition 0.000 claims description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 3
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 claims description 3
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 claims description 3
- 239000011714 flavin adenine dinucleotide Substances 0.000 claims description 3
- 229940013640 flavin mononucleotide Drugs 0.000 claims description 3
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 claims description 3
- 239000011768 flavin mononucleotide Substances 0.000 claims description 3
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 claims description 3
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 claims description 3
- 235000010382 gamma-tocopherol Nutrition 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 3
- 229930002330 retinoic acid Natural products 0.000 claims description 3
- 229960003471 retinol Drugs 0.000 claims description 3
- 235000020944 retinol Nutrition 0.000 claims description 3
- 239000011607 retinol Substances 0.000 claims description 3
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 claims description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 3
- 235000005493 rutin Nutrition 0.000 claims description 3
- 229960004555 rutoside Drugs 0.000 claims description 3
- 229960000984 tocofersolan Drugs 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 229960001295 tocopherol Drugs 0.000 claims description 3
- 229960001727 tretinoin Drugs 0.000 claims description 3
- 235000004835 α-tocopherol Nutrition 0.000 claims description 3
- 239000002076 α-tocopherol Substances 0.000 claims description 3
- 235000007680 β-tocopherol Nutrition 0.000 claims description 3
- 239000011590 β-tocopherol Substances 0.000 claims description 3
- 239000002478 γ-tocopherol Substances 0.000 claims description 3
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 claims description 3
- 239000002446 δ-tocopherol Substances 0.000 claims description 3
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 2
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 2
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 2
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 claims description 2
- 229930000083 3-dehydroretinol Natural products 0.000 claims description 2
- HRQKOYFGHJYEFS-UHFFFAOYSA-N Beta psi-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C HRQKOYFGHJYEFS-UHFFFAOYSA-N 0.000 claims description 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 2
- HDOMLWFFJSLFBI-UHFFFAOYSA-N Eriocitrin Natural products CC1OC(OCC2OC(Oc3cc(O)c4C(=O)CC(Oc4c3)c5ccc(OC6OC(COC7OC(C)C(O)C(O)C7O)C(O)C(O)C6O)c(O)c5)C(O)C(O)C2O)C(O)C(O)C1O HDOMLWFFJSLFBI-UHFFFAOYSA-N 0.000 claims description 2
- JMVXRLMOIOTWSB-PFZAOBAISA-N Eriodictin Chemical compound C[C@@H]1O[C@@H](Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O JMVXRLMOIOTWSB-PFZAOBAISA-N 0.000 claims description 2
- JMVXRLMOIOTWSB-UYVJFODRSA-N Eriodictin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1)c1cc(O)c2C(=O)C[C@H](c3cc(O)c(O)cc3)Oc2c1 JMVXRLMOIOTWSB-UYVJFODRSA-N 0.000 claims description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 2
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 claims description 2
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 claims description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 2
- 239000004213 Violaxanthin Substances 0.000 claims description 2
- SZCBXWMUOPQSOX-LOFNIBRQSA-N Violaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC34OC3(C)CC(O)CC4(C)C SZCBXWMUOPQSOX-LOFNIBRQSA-N 0.000 claims description 2
- XWCYDHJOKKGVHC-UHFFFAOYSA-N Vitamin A2 Chemical compound OCC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C XWCYDHJOKKGVHC-UHFFFAOYSA-N 0.000 claims description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 2
- 150000003835 adenosine derivatives Chemical class 0.000 claims description 2
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- SYESMXTWOAQFET-YCNIQYBTSA-N all-trans-3,4-didehydroretinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=CCC1(C)C SYESMXTWOAQFET-YCNIQYBTSA-N 0.000 claims description 2
- IUUXWKRRZDDNQG-UHFFFAOYSA-N all-trans-spheroidene Natural products COC(C)(C)CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)CCC=C(C)CCC=C(C)C IUUXWKRRZDDNQG-UHFFFAOYSA-N 0.000 claims description 2
- 239000011795 alpha-carotene Substances 0.000 claims description 2
- 235000003903 alpha-carotene Nutrition 0.000 claims description 2
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 claims description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 2
- 235000005487 catechin Nutrition 0.000 claims description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 2
- WBSXYJYELWQLCJ-UHFFFAOYSA-K cobalt(3+);[5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 1-[3-[2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,12,17-tetrahydro-1h-corrin-21-id-3-yl]propanoylamino]propan-2 Chemical compound O.[OH-].[Co+3].OCC1OC(N2C3=CC(C)=C(C)C=C3N=C2)C(O)C1OP([O-])(=O)OC(C)CNC(=O)CCC1(C)C(CC(N)=O)C2[N-]\C1=C(C)/C(C(C\1(C)C)CCC(N)=O)=N/C/1=C\C(C(C/1(CC(N)=O)C)CCC(N)=O)=N\C\1=C(C)/C1=NC2(C)C(C)(CC(N)=O)C1CCC(N)=O WBSXYJYELWQLCJ-UHFFFAOYSA-K 0.000 claims description 2
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 claims description 2
- 235000006279 cobamamide Nutrition 0.000 claims description 2
- 239000011789 cobamamide Substances 0.000 claims description 2
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 2
- 239000011666 cyanocobalamin Substances 0.000 claims description 2
- 229960002104 cyanocobalamin Drugs 0.000 claims description 2
- 235000012734 epicatechin Nutrition 0.000 claims description 2
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 2
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 claims description 2
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 claims description 2
- 235000011797 eriodictyol Nutrition 0.000 claims description 2
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 claims description 2
- 239000011663 gamma-carotene Substances 0.000 claims description 2
- 235000000633 gamma-carotene Nutrition 0.000 claims description 2
- HRQKOYFGHJYEFS-RZWPOVEWSA-N gamma-carotene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C HRQKOYFGHJYEFS-RZWPOVEWSA-N 0.000 claims description 2
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims description 2
- 229960001587 hesperetin Drugs 0.000 claims description 2
- 229940025878 hesperidin Drugs 0.000 claims description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 2
- 235000004867 hydroxocobalamin Nutrition 0.000 claims description 2
- 239000011704 hydroxocobalamin Substances 0.000 claims description 2
- 229960001103 hydroxocobalamin Drugs 0.000 claims description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 2
- 235000012680 lutein Nutrition 0.000 claims description 2
- 239000001656 lutein Substances 0.000 claims description 2
- 229960005375 lutein Drugs 0.000 claims description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 2
- 235000012661 lycopene Nutrition 0.000 claims description 2
- 239000001751 lycopene Substances 0.000 claims description 2
- 229960004999 lycopene Drugs 0.000 claims description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 2
- 235000007672 methylcobalamin Nutrition 0.000 claims description 2
- 239000011585 methylcobalamin Substances 0.000 claims description 2
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 claims description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 235000019175 phylloquinone Nutrition 0.000 claims description 2
- 239000011772 phylloquinone Substances 0.000 claims description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 claims description 2
- 229960001898 phytomenadione Drugs 0.000 claims description 2
- 229960003581 pyridoxal Drugs 0.000 claims description 2
- 235000008164 pyridoxal Nutrition 0.000 claims description 2
- 239000011674 pyridoxal Substances 0.000 claims description 2
- 235000008151 pyridoxamine Nutrition 0.000 claims description 2
- 239000011699 pyridoxamine Substances 0.000 claims description 2
- 235000008160 pyridoxine Nutrition 0.000 claims description 2
- 239000011677 pyridoxine Substances 0.000 claims description 2
- 235000005875 quercetin Nutrition 0.000 claims description 2
- 229960001285 quercetin Drugs 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 claims description 2
- FJOCMTHZSURUFA-AXYGSFPTSA-N spheroidene Chemical compound COC(C)(C)C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)CC\C=C(/C)CCC=C(C)C FJOCMTHZSURUFA-AXYGSFPTSA-N 0.000 claims description 2
- QCZWKLBJYRVKPW-LYWCOASQSA-N spheroidene Natural products COC(C)(C)CC=CC(=CC=CC(=CC=CC(=CC=CC=CC(C)C=C/C=C(C)/CCC=C(/C)CC=C(C)C)C)C)C QCZWKLBJYRVKPW-LYWCOASQSA-N 0.000 claims description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 2
- 235000019245 violaxanthin Nutrition 0.000 claims description 2
- SZCBXWMUOPQSOX-PSXNNQPNSA-N violaxanthin Chemical compound C(\[C@@]12[C@](O1)(C)C[C@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@]1(C(C[C@@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-PSXNNQPNSA-N 0.000 claims description 2
- 235000019143 vitamin K2 Nutrition 0.000 claims description 2
- 239000011728 vitamin K2 Substances 0.000 claims description 2
- 235000012711 vitamin K3 Nutrition 0.000 claims description 2
- 239000011652 vitamin K3 Substances 0.000 claims description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 2
- QHNVWXUULMZJKD-UHFFFAOYSA-N 3,4-didehydroretinal Chemical compound O=CC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C QHNVWXUULMZJKD-UHFFFAOYSA-N 0.000 claims 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims 1
- FEPAFOYQTIEEIS-UHFFFAOYSA-N 2',5'-Bis(3,4,5-trihydroxybenzoyl)-beta-D-Furanose-2-C-Hydroxymethylribose Natural products OC1C(COC(=O)C=2C=C(O)C(O)=C(O)C=2)(O)C(O)OC1COC(=O)C1=CC(O)=C(O)C(O)=C1 FEPAFOYQTIEEIS-UHFFFAOYSA-N 0.000 claims 1
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 claims 1
- FEPAFOYQTIEEIS-IZUGRSKYSA-N [(2r,3r,4r)-3,4,5-trihydroxy-4-[(3,4,5-trihydroxybenzoyl)oxymethyl]oxolan-2-yl]methyl 3,4,5-trihydroxybenzoate Chemical compound C([C@H]1OC([C@@]([C@@H]1O)(O)COC(=O)C=1C=C(O)C(O)=C(O)C=1)O)OC(=O)C1=CC(O)=C(O)C(O)=C1 FEPAFOYQTIEEIS-IZUGRSKYSA-N 0.000 claims 1
- 229950001002 cianidanol Drugs 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 150000003287 riboflavins Chemical class 0.000 claims 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 abstract description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 7
- 239000001301 oxygen Substances 0.000 abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 abstract description 7
- 230000009471 action Effects 0.000 abstract description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 3
- 108010024636 Glutathione Proteins 0.000 abstract description 2
- 230000004913 activation Effects 0.000 abstract description 2
- 230000008859 change Effects 0.000 abstract description 2
- 229960003180 glutathione Drugs 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 238000007788 roughening Methods 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 230000003647 oxidation Effects 0.000 abstract 2
- 238000007254 oxidation reaction Methods 0.000 abstract 2
- 230000003064 anti-oxidating effect Effects 0.000 abstract 1
- 125000001895 carotenoid group Chemical group 0.000 abstract 1
- 229940010007 cobalamins Drugs 0.000 abstract 1
- 235000019158 vitamin B6 Nutrition 0.000 abstract 1
- 239000011726 vitamin B6 Substances 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 239000012071 phase Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000008213 purified water Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 9
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 9
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 9
- 229960002216 methylparaben Drugs 0.000 description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 239000003205 fragrance Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 208000012641 Pigmentation disease Diseases 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 230000019612 pigmentation Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010013786 Dry skin Diseases 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 229940075507 glyceryl monostearate Drugs 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 230000002087 whitening effect Effects 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- VLYUGYAKYZETRF-UHFFFAOYSA-N dihydrolipoamide Chemical compound NC(=O)CCCCC(S)CCS VLYUGYAKYZETRF-UHFFFAOYSA-N 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 3
- UUDFBRWLHZIIQX-UHFFFAOYSA-M sodium;5-(dithiolan-3-yl)pentanoate Chemical compound [Na+].[O-]C(=O)CCCCC1CCSS1 UUDFBRWLHZIIQX-UHFFFAOYSA-M 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 229960004418 trolamine Drugs 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- NKWZDUQCHVQLPU-UHFFFAOYSA-M sodium;6,8-bis(sulfanyl)octanoate Chemical compound [Na+].[O-]C(=O)CCCCC(S)CCS NKWZDUQCHVQLPU-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical group OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 229940064063 alpha tocotrienol Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Natural products Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- COVFEVWNJUOYRL-UHFFFAOYSA-N digallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 COVFEVWNJUOYRL-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000000598 lipoate effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- NGPNWUWGVIIIDG-LEJBHHMKSA-L magnesium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-yl] phosphate Chemical class [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1OP([O-])([O-])=O NGPNWUWGVIIIDG-LEJBHHMKSA-L 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 230000037330 wrinkle prevention Effects 0.000 description 1
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 description 1
- 235000019145 α-tocotrienol Nutrition 0.000 description 1
- 239000011730 α-tocotrienol Substances 0.000 description 1
- 235000019151 β-tocotrienol Nutrition 0.000 description 1
- 239000011723 β-tocotrienol Substances 0.000 description 1
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 description 1
- 235000019150 γ-tocotrienol Nutrition 0.000 description 1
- 239000011722 γ-tocotrienol Substances 0.000 description 1
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 description 1
- 235000019144 δ-tocotrienol Nutrition 0.000 description 1
- 239000011729 δ-tocotrienol Substances 0.000 description 1
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、スーパーオキシ
ド,ヒドロキシルラジカル,過酸化物といった活性酸素
種消去活性が相乗的に増強され、肌荒れや皮膚の老化の
改善及び防止、美白作用に優れる皮膚外用剤に関する。
さらに詳しくは、リポ酸,その塩及び誘導体の1種又は
2種以上に加えて、ビタミンA及びそれらの誘導体、カ
ロテノイド類、リボフラビン及びその誘導体、ビタミン
B6,それらの塩及び誘導体、コバラミン類、ビタミン
C,その塩及び誘導体、ビタミンE及びそれらの誘導
体、ビタミンK、アデノシン及びその誘導体、フラボノ
イド類及びタンニン類より成る群から選んだ1種又は2
種以上を含有して成る皮膚外用剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an external preparation for skin which has a synergistically enhanced activity for eliminating active oxygen species such as superoxide, hydroxyl radical and peroxide, improves and prevents roughening and aging of the skin, and has an excellent whitening effect. About.
More specifically, in addition to one or more of lipoic acid, salts and derivatives thereof, vitamin A and derivatives thereof, carotenoids, riboflavin and derivatives thereof, vitamin B 6 , salts and derivatives thereof, cobalamin, One or two selected from the group consisting of vitamin C, salts and derivatives thereof, vitamin E and derivatives thereof, vitamin K, adenosine and derivatives thereof, flavonoids and tannins
The present invention relates to an external preparation for skin comprising at least one species.
【0002】[0002]
【従来の技術】紫外線や内在性酸素に起因する酸化スト
レスの皮膚に及ぼす悪影響が明らかになるにつれ、抗酸
化作用を有する物質の皮膚外用剤への応用が検討されて
きた。これら抗酸化性物質としては、ビタミンE類,ビ
タミンC類といった抗酸化性ビタミン類が代表的なもの
として挙げられる。2. Description of the Related Art As the harmful effects of oxidative stress caused by ultraviolet rays and endogenous oxygen on skin become apparent, application of substances having antioxidant activity to external preparations for skin has been studied. Representative examples of these antioxidant substances include antioxidant vitamins such as vitamin Es and vitamin Cs.
【0003】また、リポ酸も生体内で還元されることに
より、過酸化物消去作用を発揮するビタミン様物質であ
る。このリポ酸を皮膚外用剤に応用する技術も開示され
ており(特開昭62−175415)、美白剤(特開昭
63−8315,特公昭63−44123)、養毛剤
(特公平3−27524)或いは抗フケ剤(特開平2−
145507)への応用も知られている。[0003] Lipoic acid is also a vitamin-like substance that exhibits a peroxide-eliminating action by being reduced in vivo. Techniques for applying this lipoic acid to an external preparation for skin are also disclosed (JP-A-62-175415), a whitening agent (JP-A-63-8315, JP-B-63-44123), and a hair restorer (JP-B-3-27524). Alternatively, an anti-dandruff agent (Japanese Unexamined Patent Publication No.
145507) is also known.
【0004】しかしながら、上記の抗酸化性ビタミン類
は、光や酸化剤に対して不安定であったり、安定性を改
善した誘導体においても抗酸化活性が十分ではなく、皮
膚外用剤に配合して十分有効な効果を得るには、かなり
高濃度必要で、外用剤の剤型によっては溶解性の問題か
ら配合が困難であったり、製剤安定性に悪影響を及ぼし
たりすることがあった。[0004] However, the above antioxidant vitamins are unstable to light and oxidizing agents, and even derivatives having improved stability do not have sufficient antioxidant activity. In order to obtain a sufficiently effective effect, a considerably high concentration is required, and depending on the dosage form of the external preparation, formulation may be difficult due to solubility problems, or the stability of the preparation may be adversely affected.
【0005】[0005]
【発明が解決しようとする課題】従って本発明において
は、外用剤の製剤安定性に影響を与えない程度の低濃度
の抗酸化性物質を含有するのみで、優れた活性酸素種消
去作用を有し、酸化ストレスに起因する肌荒れやしわ,
しみといった皮膚の老化症状の改善,防止及び美白作用
を有する皮膚外用剤を提供することを目的とする。Accordingly, the present invention has an excellent active oxygen species elimination effect only by containing a low concentration of an antioxidant substance which does not affect the preparation stability of an external preparation. Skin roughness and wrinkles caused by oxidative stress,
It is an object of the present invention to provide an external preparation for skin having an effect of improving, preventing and whitening skin aging symptoms such as spots.
【0006】[0006]
【課題を解決するための手段】上記の課題を解決するた
め種々検討を行ったところ、リポ酸,その塩及び誘導体
の1種又は2種以上に加えて、ビタミンA及びそれらの
誘導体、カロテノイド類、リボフラビン及びその誘導
体、ビタミンB6,それらの塩及び誘導体、コバラミン
類、ビタミンC,その塩及び誘導体、ビタミンE及びそ
れらの誘導体、ビタミンK、アデノシン及びその誘導
体、フラボノイド類及びタンニン類より成る群から選ん
だ1種又は2種以上を含有させることにより、活性酸素
種消去作用が相乗的に向上することを見い出した。その
結果、前記リポ酸等の1種又は2種以上及びビタミンA
等の1種又は2種以上を、それぞれ皮膚外用剤の製剤安
定性に影響を与えない程度の低濃度配合するのみで、有
効な肌荒れや皮膚の老化症状の改善,防止作用、及び美
白作用を発揮させることができた。Various studies have been made to solve the above-mentioned problems. In addition to one or more of lipoic acid, its salts and derivatives, vitamin A and its derivatives, carotenoids , riboflavin and its derivatives, vitamin B 6, their salts and derivatives, cobalamin compounds, vitamin C, salts and derivatives thereof, vitamin E and derivatives thereof, vitamin K, adenosine and derivatives thereof, the group consisting of flavonoids and tannins It has been found that by containing one or more selected from the group, the action of eliminating active oxygen species is synergistically improved. As a result, one or more kinds of the lipoic acid and the like and vitamin A
One or two or more of these compounds can be combined with each other at a low concentration that does not affect the stability of the external preparation for skin. I was able to demonstrate.
【0007】本発明において用いるリポ酸の塩及び誘導
体としては、ナトリウム塩,カリウム塩,アルキルエス
テル,アルケニルエステル,アミド類、及び還元体のジ
ヒドロリポ酸,ジヒドロリポアミド等が挙げられ、これ
らより1種又は2種以上を選択して用いる。特に、リポ
酸のアルキルエステル,アルケニルエステル,アミド,
ジヒドロリポ酸及びジヒドロリポアミドが好ましい。The lipoic acid salts and derivatives used in the present invention include sodium salts, potassium salts, alkyl esters, alkenyl esters, amides, and reduced dihydrolipoic acids and dihydrolipoamides. Alternatively, two or more kinds are selected and used. In particular, lipoic acid alkyl esters, alkenyl esters, amides,
Dihydrolipoic acid and dihydrolipoamide are preferred.
【0008】また、本発明においてリポ酸類と併用して
含有させる生理活性物質のうち、ビタミンA類として
は、レチノール,そのエステル,レチナール,レチノイ
ン酸,そのエステル,3-デヒドロレチノール,そのエス
テル,3-デヒドロレチナール,3-デヒドロレチノイン酸
及びそのエステルが好適な例として挙げられる。前記の
他に、水溶性ビタミン類,α-ヒドロキシ酸との複合体
(特開平8−73338,同8−73312)も用いる
ことができる。Among the physiologically active substances contained in combination with the lipoic acids in the present invention, vitamin A includes retinol, its ester, retinal, retinoic acid, its ester, 3-dehydroretinol, its ester, Preferred examples include -dehydroretinal, 3-dehydroretinoic acid and esters thereof. In addition to the above, complexes with water-soluble vitamins and α-hydroxy acids (JP-A-8-73338 and JP-A-8-73312) can also be used.
【0009】カロテノイド類としては、α-カロテン,
β-カロテン,γ-カロテン,リコペン,ルテイン,ビオ
ラキサンチン,スピリロキサンチン,スフェロイデン,
アスタキサンチン等が好ましいものとして挙げられ、こ
れらより1種又は2種以上を選択して用いる。As carotenoids, α-carotene,
β-carotene, γ-carotene, lycopene, lutein, violaxanthin, spiriroxanthin, spheroidene,
Astaxanthin and the like are mentioned as preferable ones, and one or two or more kinds are selected from these and used.
【0010】リボフラビンはビタミンB2といわれる水
溶性ビタミンである。その誘導体としては、フラビンア
デニンジヌクレオチド(FAD)及びフラビンモノヌク
レオチド(FMN)が挙げられ、これらより1種又は2
種を選択して用いる。[0010] Riboflavin is a water-soluble vitamin which is referred to as vitamin B 2. Derivatives thereof include flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN).
Select and use seeds.
【0011】ビタミンB6及びそれらの塩としては、ピ
リドキシン,ピリドキサール,ピリドキサミン及びこれ
らの塩が挙げられ、これらより1種又は2種以上を選択
して用いる。Examples of vitamin B 6 and salts thereof include pyridoxine, pyridoxal, pyridoxamine and salts thereof, and one or more of these are selected and used.
【0012】コバラミン類としては、ビタミンB12であ
るシアノコバラミン、及びその関連化合物であるメチル
コバラミン,アデノシルコバラミン,ヒドロキソコバラ
ミン,アクアコバラミン等が挙げられ、これらより1種
又は2種以上を選択して用いる。[0012] As cobalamin compound is cyanocobalamin is vitamin B 12, and methylcobalamin is related compounds, adenosylcobalamin, hydroxocobalamin, Aqua cobalamin and the like, to select one or more from these Used.
【0013】ビタミンC,その塩及び誘導体としては、
アスコルビン酸,デヒドロアスコルビン酸及びこれらの
塩、アスコルビン酸リン酸エステル,ホスファチジルア
スコルビン酸及びこれらの塩等が好ましいものとして挙
げられる。また、トコフェロール,アスタキサンチンと
の複合体(特開昭63−139114,国際公開92/
07544,特開平8−73311)等も用いることが
できる。As vitamin C, its salts and derivatives,
Ascorbic acid, dehydroascorbic acid and salts thereof, ascorbic acid phosphate, phosphatidyl ascorbic acid and salts thereof are preferred. Further, a complex with tocopherol and astaxanthin (JP-A-63-139114, International Publication 92/92)
07544, JP-A-8-73311) can also be used.
【0014】ビタミンE及びそれらの誘導体としては、
α-トコフェロール,β-トコフェロール,γ-トコフェ
ロール,δ-トコフェロール,及びこれらの酢酸エステ
ル,ニコチン酸エステル等が好ましいものとして挙げら
れ、これらより1種又は2種以上を選択して用いる。ま
た、α-トコトリエノール,β-トコトリエノール,γ-
トコトリエノール,δ-トコトリエノールの他、α-ヒド
ロキシ酸との複合体(特開平6−279258)等も用
いることができる。Vitamin E and derivatives thereof include:
Preferred are α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, and acetates and nicotinates thereof, and one or more of these are selected and used. Α-tocotrienol, β-tocotrienol, γ-tocotrienol
In addition to tocotrienol and δ-tocotrienol, complexes with α-hydroxy acids (JP-A-6-279258) and the like can also be used.
【0015】ビタミンKとしては、フィロキノン,メナ
キノン及びメナジオンが挙げられ、これらより1種又は
2種以上を選択して用いることができる。Examples of vitamin K include phylloquinone, menaquinone and menadione, and one or more of these can be selected and used.
【0016】アデノシンの誘導体としては、ビタミンL
2として知られる5'-メチルチオアデノシン、酸化的リン
酸化やストレス応答に関与するアデノシン一リン酸(A
MP),環状アデノシン一リン酸(c-AMP),アデノ
シン二リン酸(ADP)及びアデノシン三リン酸(AT
P)が挙げられ、これらより1種又は2種以上を選択し
て用いる。As adenosine derivatives, vitamin L
2 ' , adenosine monophosphate (A) involved in oxidative phosphorylation and stress response
MP), cyclic adenosine monophosphate (c-AMP), adenosine diphosphate (ADP) and adenosine triphosphate (AT
P), and one or more of these are selected and used.
【0017】フラボノイド類としては、カテキン類、ビ
タミンPとして知られるヘスペリジン及びルチン、ビタ
ミンP様作用を有するヘスペリチン,クウェルセチン,
エリオジクチオール,エリオジクチン及びエピカテキン
等が好ましいものとして挙げられ、これらより1種又は
2種以上を選択して用いる。Examples of flavonoids include catechins, hesperidin and rutin known as vitamin P, hesperitin having a vitamin P-like action, quercetin,
Preference is given to eriodictyol, eriodictin, epicatechin and the like, and one or more of these are selected and used.
【0018】タンニン類としては、フラバノール骨格が
重合した縮合型タンニン、加水分解により没食子酸,エ
ラグ酸等の芳香族有機酸を生成し、これらと糖がデプシ
ド結合した加水分解型タンニン、及びタンニン酸と呼ば
れるm-ガロイル没食子酸が挙げられ、これらより1種又
は2種以上を選択して用いることができる。活性酸素種
消去作用の強さから、ハマメリタンニン及び茶タンニン
が特に好ましい。The tannins include condensed tannins in which a flavanol skeleton is polymerized, hydrolyzed tannins in which aromatic organic acids such as gallic acid and ellagic acid are formed by hydrolysis, and these are sugar-depside-bonded, and tannic acids. M-galloyl gallic acid, and one or more of these can be selected and used. Hamamellitannin and tea tannin are particularly preferred from the viewpoint of the effect of eliminating active oxygen species.
【0019】本発明においては、上記リポ酸類の1種又
は2種以上、及びビタミンA類,カロテノイド類,リボ
フラビン類,ビタミンB6類,コバラミン類,ビタミン
C類,ビタミンE類,ビタミンK類,アデノシン類,フ
ラボノイド類及びタンニン類より選択される1種又は2
種以上は、直接水性又は油性の溶媒に溶解させて含有さ
せることができるが、界面活性剤によるミセルに取り込
ませたり、マイクロカプセル化或いはリポソーム化して
含有させることもできる。これらの皮膚外用剤全量に対
する配合量は、それぞれ0.01〜10.0重量%程度
が適当である。In the present invention, the lipoic acid one or two or more, and vitamin A, carotenoids, riboflavin, vitamin B 6 such cobalamin, vitamin C, vitamin E, vitamin K compound, One or two selected from adenosines, flavonoids and tannins
The species or more can be contained by directly dissolving them in an aqueous or oily solvent, but they can also be incorporated into micelles by a surfactant, or microcapsules or liposomes. The appropriate amount of each of these external preparations for skin is about 0.01 to 10.0% by weight.
【0020】なお本発明においては、本発明の構成成分
であるリポ酸類及びビタミンA類等の抗酸化性物質の活
性に悪影響を及ぼさない範囲で、油類,多価アルコー
ル,多糖類,水溶性高分子,界面活性剤,紫外線吸収
剤,酸化防止剤,抗菌防腐剤,抗炎症剤,生理活性物
質,香料等、一般的に使用される他の皮膚外用剤又は化
粧料用原料を含有させることもできる。In the present invention, oils, polyhydric alcohols, polysaccharides, water-soluble substances, etc. are used as long as they do not adversely affect the activity of antioxidant substances such as lipoic acids and vitamin A which are constituents of the present invention. Contains other commonly used skin external agents or cosmetic ingredients such as polymers, surfactants, ultraviolet absorbers, antioxidants, antimicrobial preservatives, anti-inflammatory agents, biologically active substances, fragrances, etc. Can also.
【0021】[0021]
【作用】本発明に係る皮膚外用剤は、皮膚に適用するこ
とにより、皮膚内で生成する外因性及び内因性の活性酸
素種をより有効に消去し、さらに内因性のグルタチオン
レベルの上昇等、生体内抗酸化機構の活性化を介して、
肌荒れやしわなどの皮膚における酸化ストレスに起因す
る老化症状を改善し、さらにはその進行を抑制する。ま
た、紫外線による日焼けや老化に伴い発生する皮膚のし
みをも改善し、それらの発生を防止する。The external preparation for skin according to the present invention, when applied to the skin, effectively eliminates exogenous and endogenous reactive oxygen species generated in the skin, and further increases endogenous glutathione levels. Through activation of the antioxidant mechanism in vivo,
Improves aging symptoms caused by oxidative stress in the skin such as rough skin and wrinkles, and further suppresses its progress. In addition, it also improves skin spots caused by sunburn and aging caused by ultraviolet rays, and prevents the occurrence of such spots.
【0022】[0022]
【発明の実施の形態】本発明は、ローション剤,乳剤,
ゲル剤,クリーム,軟膏等の形態の皮膚外用剤として、
また化粧水,乳液,クリーム,マッサージ剤,パック剤
等の皮膚用化粧料、乳液状或いはクリーム状ファンデー
ション等のメイクアップ化粧料として実施することがで
きる。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a lotion, an emulsion,
As an external preparation for skin in the form of gels, creams, ointments, etc.
It can also be used as a skin cosmetic such as a lotion, an emulsion, a cream, a massage agent, a pack, and the like, and a makeup cosmetic such as an emulsion or a creamy foundation.
【0023】[0023]
【実施例】さらに本発明について、実施例により詳細に
説明する。EXAMPLES The present invention will be described in more detail with reference to Examples.
【0024】 [実施例1] 皮膚用ローション剤 (1)エタノール 10.0(重量%) (2)ヒドロキシエチルセルロース 1.0 (3)アスコルビン酸内包リポソーム 5.0 (内包率;3.0重量%) (4)リポ酸 1.0 (5)精製水 83.0 製法:(1),(2),(4)及び(5)を混合し均一とした後、
(3)を添加,分散させる。[Example 1] Lotion for skin (1) Ethanol 10.0 (wt%) (2) Hydroxyethylcellulose 1.0 (3) Ascorbic acid-encapsulated liposome 5.0 (encapsulation rate: 3.0% by weight) (4) Lipoic acid 1.0 (5) Purified water 83.0 Production method: After mixing (1), (2), (4) and (5) to make uniform,
Add and disperse (3).
【0025】 [実施例2] 皮膚用乳剤 (1)ステアリン酸 0.2(重量%) (2)セタノール 1.5 (3)ワセリン 3.0 (4)流動パラフィン 7.0 (5)ポリオキシエチレン(10E.O.)モノオレイン酸 1.5 エステル (6)酢酸トコフェロール 5.0 (7)リポ酸メチルエステル内包リポソーム 10.0 (内包率;2.5重量%) (8)グリセリン 5.0 (9)パラオキシ安息香酸メチル 0.1 (10)トリエタノールアミン 1.0 (11)精製水 65.7 製法:(1)〜(6)の油相成分を混合,加熱して均一に溶解
し、70℃に保つ。一方、(8)〜(11)の水相成分を混
合,加熱して均一とし、70℃とする。この水相成分に
前記油相成分を攪拌しながら徐々に添加して乳化させ、
冷却した後(7)を添加,分散する。Example 2 Emulsion for skin (1) Stearic acid 0.2 (% by weight) (2) Cetanol 1.5 (3) Vaseline 3.0 (4) Liquid paraffin 7.0 (5) Polyoxy Ethylene (10E.O.) monooleic acid 1.5 ester (6) Tocopherol acetate 5.0 (7) Lipoic acid methyl ester-encapsulated liposome 10.0 (encapsulation rate; 2.5% by weight) (8) Glycerin 5. 0 (9) Methyl parahydroxybenzoate 0.1 (10) Triethanolamine 1.0 (11) Purified water 65.7 Production method: Mix the oil phase components (1) to (6) and heat to dissolve uniformly And maintain at 70 ° C. On the other hand, the aqueous phase components (8) to (11) are mixed and heated to be uniform, and the temperature is set to 70 ° C. The oil phase component is gradually added to the aqueous phase component while stirring to emulsify,
After cooling, add (7) and disperse.
【0026】 [実施例3] 皮膚用ゲル剤 (1)ジプロピレングリコール 10.0(重量%) (2)カルボキシビニルポリマー 0.5 (3)水酸化カリウム 0.1 (4)パラオキシ安息香酸メチル 0.1 (5)アスコルビン酸リン酸エステルマグネシウム塩 4.0 (6)ニコチン酸トコフェロール内包リポソーム 4.0 (内包率;3.5重量%) (7)リポ酸内包リポソーム 5.0 (内包率;2.5重量%) (8)精製水 76.3 製法:(8)に(2)を均一に溶解させた後、(1)に(4)を溶解
させて添加し、次いで(3)を加えて増粘させ、(5)〜(7)
を添加し、溶解又は分散させる。Example 3 Skin Gel (1) Dipropylene glycol 10.0 (% by weight) (2) Carboxyvinyl polymer 0.5 (3) Potassium hydroxide 0.1 (4) Methyl paraoxybenzoate 0.1 (5) Magnesium ascorbic acid phosphate ester 4.0 (6) Liposomes containing tocopherol nicotinate 4.0 (encapsulation rate: 3.5% by weight) (7) Liposomes containing lipoic acid 5.0 (encapsulation rate) 2.5% by weight) (8) Purified water 76.3 Production method: After dissolving (2) uniformly in (8), dissolve (4) in (1) and then add (3) (5)-(7)
Is added and dissolved or dispersed.
【0027】 [実施例4] 皮膚用クリーム (1)ミツロウ 6.0(重量%) (2)セタノール 5.0 (3)還元ラノリン 8.0 (4)スクワラン 37.5 (5)グリセリル脂肪酸エステル 4.0 (6)親油型グリセリルモノステアリン酸エステル 2.0 (7)ポリオキシエチレン(20E.O.)ソルビタン 5.0 モノラウリン酸エステル (8)ジヒドロリポ酸 1.0 (9)レチノールパルミチン酸エステル 1.0 (10)プロピレングリコール 5.0 (11)パラオキシ安息香酸メチル 0.1 (12)精製水 25.4 製法:(1)〜(7)の油相成分を混合,溶解して75℃に加
熱する。一方、(10)〜(12)の水相成分を混合,溶解して
75℃に加熱する。次いで、上記水相成分に油相成分を
添加して予備乳化した後、ホモミキサーにて均一に乳化
し、冷却後40℃にて(8),(9)を添加,混合する。Example 4 Skin Cream (1) Beeswax 6.0 (% by weight) (2) Cetanol 5.0 (3) Reduced Lanolin 8.0 (4) Squalane 37.5 (5) Glyceryl fatty acid ester 4.0 (6) Lipophilic glyceryl monostearate 2.0 (7) Polyoxyethylene (20E.O.) sorbitan 5.0 Monolaurate (8) Dihydrolipoic acid 1.0 (9) Retinol palmitic acid Ester 1.0 (10) Propylene glycol 5.0 (11) Methyl parahydroxybenzoate 0.1 (12) Purified water 25.4 Production method: Mix and dissolve oil phase components (1) to (7) to 75 Heat to ° C. On the other hand, the aqueous phase components (10) to (12) are mixed and dissolved and heated to 75 ° C. Next, the oil phase component is added to the water phase component and pre-emulsified, and then uniformly emulsified by a homomixer. After cooling, (8) and (9) are added and mixed at 40 ° C.
【0028】 [実施例5] 水中油型乳剤性軟膏 (1)白色ワセリン 25.00(重量%) (2)ステアリルアルコール 25.00 (3)グリセリン 12.00 (4)ラウリル硫酸ナトリウム 1.00 (5)乳酸トコフェロールホスフォジエステル 0.05 (6)レチノイン酸 0.50 (7)リポ酸エチルエステル 0.25 (8)ジヒドロリポアミド 0.25 (9)パラオキシ安息香酸メチル 0.10 (10)アスコルビン酸リン酸エステルマグネシウム塩 0.10 (11)精製水 35.75 製法:(1)〜(5)の油相成分を混合,溶解して均一とし、
75℃に加熱する。一方、(9)及び(11)の水相成分を混
合,溶解して75℃に加熱し、これに前記油相成分を添
加して乳化し、冷却後40℃にて(6)〜(8)及び(10)を添
加,混合する。Example 5 Oil-in-water emulsion ointment (1) White petrolatum 25.00 (% by weight) (2) Stearyl alcohol 25.00 (3) Glycerin 12.00 (4) Sodium lauryl sulfate 1.00 (5) Lactic acid tocopherol phosphodiester 0.05 (6) Retinoic acid 0.50 (7) Lipoic acid ethyl ester 0.25 (8) Dihydrolipoamide 0.25 (9) Methyl parahydroxybenzoate 0.10 (10 ) Ascorbic acid phosphate magnesium salt 0.10 (11) Purified water 35.75 Production method: Mix and dissolve the oil phase components of (1) to (5) to make uniform,
Heat to 75 ° C. On the other hand, the aqueous phase components (9) and (11) were mixed and dissolved, heated to 75 ° C., and the oil phase component was added thereto to emulsify. ) And (10) are added and mixed.
【0029】 [実施例6] 化粧水 (1)エタノール 10.00(重量%) (2)1,3-ブチレングリコール 5.00 (3)パラオキシ安息香酸メチル 0.10 (4)β-カロテン 0.02 (5)リポ酸ナトリウム 0.02 (6)香料 0.10 (7)精製水 84.76 製法:(1)〜(6)を順次(7)に添加して均一に混合,溶解
する。Example 6 Lotion (1) Ethanol 10.00 (% by weight) (2) 1,3-butylene glycol 5.00 (3) Methyl parahydroxybenzoate 0.10 (4) β-carotene 0 0.02 (5) Sodium lipoate 0.02 (6) Fragrance 0.10 (7) Purified water 84.76 Production method: (1) to (6) are sequentially added to (7) and uniformly mixed and dissolved .
【0030】 [実施例7] 乳液 (1)スクワラン 5.0(重量%) (2)ワセリン 2.0 (3)ミツロウ 0.5 (4)ソルビタンセスキオレイン酸エステル 0.8 (5)ポリオキシエチレン(20E.O.)ソルビタン 1.2 モノラウリン酸エステル (6)プロピレングリコール 5.0 (7)カルボキシビニルポリマー1.0重量%水溶液 20.0 (8)水酸化カリウム 0.1 (9)パラオキシ安息香酸メチル 0.1 (10)アデノシン三リン酸 0.1 (11)ジヒドロリポ酸ナトリウム 0.1 (12)香料 0.1 (13)精製水 65.0 製法:(1)〜(5)の油相成分を混合,加熱して70℃とす
る。一方、(6),(9),(13)の水相成分を混合,加熱して
70℃とし、これに前記油相を加えて予備乳化し、次い
で(7)を加えて均一に混和した後、(8)を加えて中和し、
ホモミキサーにて均一に乳化して冷却する。冷却後、4
0℃にて(10)〜(12)を添加し、均一に混合する。Example 7 Emulsion (1) Squalane 5.0 (% by weight) (2) Vaseline 2.0 (3) Beeswax 0.5 (4) Sorbitan sesquioleate 0.8 (5) Polyoxy Ethylene (20E.O.) Sorbitan 1.2 Monolaurate (6) Propylene glycol 5.0 (7) 1.0% by weight aqueous solution of carboxyvinyl polymer 20.0 (8) Potassium hydroxide 0.1 (9) Paraoxy Methyl benzoate 0.1 (10) Adenosine triphosphate 0.1 (11) Sodium dihydrolipoate 0.1 (12) Fragrance 0.1 (13) Purified water 65.0 Production methods: (1) to (5) The oil phase components are mixed and heated to 70 ° C. On the other hand, the aqueous phase components (6), (9) and (13) were mixed and heated to 70 ° C., and the oil phase was added thereto for pre-emulsification, and then (7) was added and uniformly mixed. Later, add (8) to neutralize,
Emulsify uniformly with a homomixer and cool. After cooling, 4
At 0 ° C., add (10) to (12) and mix uniformly.
【0031】 [実施例8] 保湿クリーム(水中油型) (1)ステアリルアルコール 6.0(重量%) (2)ステアリン酸 2.0 (3)水素添加ラノリン 4.0 (4)スクワラン 9.0 (5)オクチルドデカノール 10.0 (6)ポリオキシエチレン(25E.O.)セチルアルコール 3.0 エーテル (7)グリセリルモノステアリン酸エステル 2.0 (8)1,3-ブチレングリコール 6.0 (9)パラオキシ安息香酸メチル 0.1 (10)ハマメリタンニン 0.1 (11)リポ酸カリウム 0.3 (12)香料 0.1 (13)精製水 57.4 製法:(1)〜(7)の油相成分を混合,加熱して70℃とす
る。一方、(8),(9)及び(13)の水相成分を混合,加熱し
て70℃とし、これに前記油相を添加して乳化させ、冷
却後40℃にて(10)〜(12)を添加し、均一に混合する。[Example 8] Moisturizing cream (oil-in-water type) (1) Stearyl alcohol 6.0 (% by weight) (2) Stearic acid 2.0 (3) Hydrogenated lanolin 4.0 (4) Squalane 9. 0 (5) octyl dodecanol 10.0 (6) polyoxyethylene (25E.O.) cetyl alcohol 3.0 ether (7) glyceryl monostearate 2.0 (8) 1,3-butylene glycol 6. 0 (9) Methyl parahydroxybenzoate 0.1 (10) Hamametannin 0.1 (11) Potassium lipoate 0.3 (12) Fragrance 0.1 (13) Purified water 57.4 Production method: (1)- The oil phase component of (7) is mixed and heated to 70 ° C. On the other hand, the aqueous phase components of (8), (9) and (13) were mixed and heated to 70 ° C., and the oil phase was added thereto to emulsify. After cooling, (10) to (10) Add 12) and mix uniformly.
【0032】 [実施例9] エモリエントクリーム(油中水型) (1)流動パラフィン 30.0(重量%) (2)マイクロクリスタリンワックス 2.0 (3)ワセリン 5.0 (4)ジグリセリルジオレイン酸エステル 5.0 (5)L-グルタミン酸ナトリウム 1.6 (6)L-セリン 0.4 (7)プロピレングリコール 3.0 (8)パラオキシ安息香酸メチル 0.1 (9)ルチン 0.2 (10)リポ酸アミド 0.5 (11)香料 0.1 (12)精製水 52.1 製法:(5),(6)を(12)の一部に溶解して50℃とし、5
0℃に加熱した(4)に攪拌しながら徐々に添加する。こ
れをあらかじめ混合し70℃に加熱溶解した(1)〜(3)に
均一に分散し、これに(7),(8)を(12)の残部に溶解して
70℃に加熱したものを攪拌しながら添加し、ホモミキ
サーにて乳化する。冷却後、40℃にて(9)〜(11)を添
加,混合する。[Example 9] Emollient cream (water-in-oil type) (1) Liquid paraffin 30.0 (% by weight) (2) Microcrystalline wax 2.0 (3) Vaseline 5.0 (4) Diglyceryl geo Maleic ester 5.0 (5) Sodium L-glutamate 1.6 (6) L-serine 0.4 (7) Propylene glycol 3.0 (8) Methyl parahydroxybenzoate 0.1 (9) Rutin 0.2 (10) Lipoic acid amide 0.5 (11) Fragrance 0.1 (12) Purified water 52.1 Production method: (5) and (6) are dissolved in a part of (12) to 50 ° C.
Add slowly to (4) heated to 0 ° C. with stirring. This was previously mixed and uniformly dispersed in (1) to (3), which were heated and dissolved at 70 ° C., and (7) and (8) were dissolved in the remainder of (12) and heated to 70 ° C. Add while stirring and emulsify with a homomixer. After cooling, (9) to (11) are added and mixed at 40 ° C.
【0033】 [実施例10] メイクアップベースクリーム (1)ステアリン酸 12.00(重量%) (2)セタノール 2.00 (3)自己乳化型グリセリルモノステアリン酸エステル 2.00 (4)ビタミンK 0.25 (5)プロピレングリコール 10.00 (6)水酸化カリウム 0.30 (7)パラオキシ安息香酸メチル 0.10 (8)リポ酸ナトリウム 0.25 (9)香料 0.10 (10)精製水 71.50 (11)二酸化チタン 1.00 (12)ベンガラ 0.10 (13)黄酸化鉄 0.40 製法:(11)〜(13)を(5)で練り、これを(6),(7),(10)
の水相に添加,混合し、70℃に加熱する。一方、(1)
〜(4)の油相成分を混合,加熱して70℃とし、これを
前記水相に攪拌しながら添加して乳化する。乳化後冷却
して40℃にて(8),(9)を添加,混合する。Example 10 Makeup Base Cream (1) Stearic acid 12.00 (% by weight) (2) Cetanol 2.00 (3) Self-emulsifying glyceryl monostearate 2.00 (4) Vitamin K 0.25 (5) Propylene glycol 10.00 (6) Potassium hydroxide 0.30 (7) Methyl parahydroxybenzoate 0.10 (8) Sodium lipoate 0.25 (9) Fragrance 0.10 (10) Purification Water 71.50 (11) Titanium dioxide 1.00 (12) Bengala 0.10 (13) Yellow iron oxide 0.40 Production method: (11) to (13) are kneaded with (5), and this is kneaded with (6), (7), (10)
, Mixed and heated to 70 ° C. On the other hand, (1)
The oil phase components (4) to (4) are mixed and heated to 70 ° C., and the mixture is added to the aqueous phase with stirring to emulsify. After emulsification, cool and add (8) and (9) at 40 ° C and mix.
【0034】 [実施例11] 乳液状ファンデーション (1)ステアリン酸 2.4(重量%) (2)モノステアリン酸プロピレングリコール 2.0 (3)セトステアリルアルコール 0.2 (4)液状ラノリン 2.0 (5)流動パラフィン 3.0 (6)ミリスチン酸イソプロピル 8.5 (7)カルボキシメチルセルロースナトリウム 0.2 (8)ベントナイト 0.5 (9)プロピレングリコール 4.0 (10)トリエタノールアミン 1.1 (11)パラオキシ安息香酸メチル 0.1 (12)塩酸ピリドキシン 0.1 (13)ジヒドロリポ酸ナトリウム 0.1 (14)香料 0.1 (15)精製水 57.7 (16)酸化チタン 8.0 (17)タルク 4.0 (18)ベンガラ 3.0 (19)黄酸化鉄 2.5 (20)黒酸化鉄 0.5 製法:(16)〜(20)の顔料を混合後、粉砕機により粉砕す
る。(15)を70℃に加熱し、(8)を加えてよく膨潤さ
せ、これにあらかじめ(7)を(9)に分散させたものを加
え、さらに(10),(11)を添加し、溶解させる。(1)〜(6)
の油相は混合し、加熱,溶解して80℃とする。前記顔
料を水相に攪拌しながら加え、コロイドミルを通して7
5℃とし、前記油相を攪拌しながら加えて乳化し、冷却
後40℃にて(12)〜(14)を添加,混合する。Example 11 Emulsion Foundation (1) Stearic acid 2.4 (% by weight) (2) Propylene glycol monostearate 2.0 (3) Cetostearyl alcohol 0.2 (4) Liquid lanolin 0 (5) Liquid paraffin 3.0 (6) Isopropyl myristate 8.5 (7) Sodium carboxymethyl cellulose 0.2 (8) Bentonite 0.5 (9) Propylene glycol 4.0 (10) Triethanolamine 1. 1 (11) Methyl parahydroxybenzoate 0.1 (12) Pyridoxine hydrochloride 0.1 (13) Sodium dihydrolipoate 0.1 (14) Fragrance 0.1 (15) Purified water 57.7 (16) Titanium oxide 0 (17) Talc 4.0 (18) Bengala 3.0 (19) Yellow iron oxide 2.5 (20) Black iron oxide 0.5 Manufacturing method: After mixing pigments of (16) to (20), pulverizer And pulverize. (15) was heated to 70 ° C., (8) was added to swell well, to which was added (7) previously dispersed in (9), and (10) and (11) were added. Allow to dissolve. (1)-(6)
Are mixed, heated and melted to 80 ° C. The pigment is added to the aqueous phase with stirring and passed through a colloid mill for 7 minutes.
The temperature was adjusted to 5 ° C, the oil phase was added with stirring to emulsify, and after cooling, (12) to (14) were added and mixed at 40 ° C.
【0035】 [実施例12」 クリーム状ファンデーション (1)ステアリン酸 5.00(重量%) (2)親油型グリセリルモノステアリン酸エステル 2.50 (3)モノラウリン酸プロピレングリコール 3.00 (4)セトステアリルアルコール 1.00 (5)流動パラフィン 7.00 (6)ミリスチン酸イソプロピル 8.00 (7)β-カロテン 0.10 (8)アスタキサンチン 0.05 (9)ソルビトール 3.00 (10)トリエタノールアミン 1.20 (11)パラオキシ安息香酸メチル 0.15 (12)リポ酸ナトリウム 0.15 (13)ジヒドロリポアミド 0.02 (14)香料 0.15 (15)精製水 47.68 (16)酸化チタン 8.00 (17)カオリン 5.00 (18)タルク 2.00 (19)ベントナイト 1.00 (20)ベンガラ 2.60 (21)黄酸化鉄 2.10 (22)黒酸化鉄 0.30 製法:(16)〜(22)の顔料を混合後、粉砕機により粉砕す
る。(9)〜(11),(15)を混合,溶解して加熱する。(1)〜
(8)の油相は混合し、加熱,溶解して80℃とする。前
記顔料を水相に攪拌しながら加え、コロイドミルを通し
て75℃とし、前記油相を攪拌しながら加えて乳化し、
冷却後40℃にて(12)〜(14)を添加,混合する。Example 12 Cream Foundation (1) Stearic acid 5.00 (% by weight) (2) Lipophilic glyceryl monostearate 2.50 (3) Propylene glycol monolaurate 3.00 (4) Cetostearyl alcohol 1.00 (5) Liquid paraffin 7.00 (6) Isopropyl myristate 8.00 (7) β-carotene 0.10 (8) Astaxanthin 0.05 (9) Sorbitol 3.00 (10) Tri Ethanolamine 1.20 (11) Methyl parahydroxybenzoate 0.15 (12) Sodium lipoate 0.15 (13) Dihydrolipoamide 0.02 (14) Fragrance 0.15 (15) Purified water 47.68 (16 ) Titanium oxide 8.00 (17) Kaolin 5.00 (18) Talc 2.00 (19) Bentonite 1.00 (20) Bengala 2.60 (21) Yellow iron oxide 2.10 (22) Black iron oxide 0 .30 Production method: (16) After mixing the pigments of (22) to (22), the mixture is pulverized by a pulverizer. (9) to (11), (15) are mixed, dissolved and heated. (1) 〜
The oil phase of (8) is mixed, heated and dissolved to 80 ° C. The pigment is added to the aqueous phase with stirring, brought to 75 ° C. through a colloid mill, and the oil phase is added with stirring and emulsified,
After cooling, add (12) to (14) at 40 ° C and mix.
【0036】上記の実施例のうち実施例1,実施例2及
び実施例4について、使用試験を行った。その際、表1
〜表3に示す比較例1〜比較例6についても、同時に試
験を行った。これら比較例は、それぞれ実施例1,実施
例2及び実施例4と同様に調製した。A use test was conducted on Examples 1, 2 and 4 among the above Examples. At that time, Table 1
-About the comparative example 1-the comparative example 6 shown in Table 3, the test was also performed simultaneously. These comparative examples were prepared in the same manner as in Example 1, Example 2 and Example 4, respectively.
【表1】 [Table 1]
【表2】 [Table 2]
【表3】 [Table 3]
【0037】(1)肌荒れの改善効果 顕著な肌荒れ症状
を有する女性パネラー20名を1群とし、各群に実施例
及び比較例のそれぞれを1日2回、ブラインドにて1カ
月間連続使用させ、1カ月後の皮膚の症状を観察して、
使用開始前と比較した。皮膚の肌荒れ症状は表4に示す
判定基準に従って点数化し、20名の平均値を算出し
た。(1) Effect of improving skin roughness A group of 20 female panelists having remarkable skin roughness symptoms was allowed to use each of the examples and comparative examples twice a day in a blind continuously for one month. 1 month after observing the skin symptoms,
The comparison was made before the start of use. The skin roughness symptoms were scored according to the criteria shown in Table 4, and the average value of 20 persons was calculated.
【表4】 [Table 4]
【0038】(2)しわの防止効果 ヘアレスマウス5匹
を1群とし、各群について実施例及び比較例をそれぞれ
1日1回背部に塗布し、1J/cm2/週の長波長紫外線
(UVA)を50週間照射した。ヘアレスマウス背部皮
膚におけるしわの発生状況は、表5に示す判定基準に従
って評価し、各群の平均値を求め、UVA照射日数との
関係を求めた。なお、精製水を同様に塗布した群を対照
とした。(2) Wrinkle Prevention Effect Five hairless mice were grouped into one group, and the examples and comparative examples of each group were applied once a day to the back once a day, and 1 J / cm 2 / week long wavelength ultraviolet (UVA) ) Was irradiated for 50 weeks. The occurrence of wrinkles on the back skin of the hairless mouse was evaluated according to the criteria shown in Table 5, the average value of each group was determined, and the relationship with the number of days of UVA irradiation was determined. A group to which purified water was similarly applied was used as a control.
【表5】 [Table 5]
【0039】(3)色素沈着症状の改善効果 顕著なシ
ミ,ソバカス等の色素沈着症状を有する女性パネラー2
0名を1群とし、各群に実施例及び比較例をそれぞれブ
ラインドにて1日2回ずつ1カ月間使用させ、1カ月後
の皮膚の色素沈着の状態を観察して使用前と比較した。
色素沈着の状況は表6に示す判定基準に従って評価し、
20名の平均値を算出した。(3) Improvement effect of pigmentation symptoms Female paneler 2 having remarkable pigmentation symptoms such as spots and freckles
0 group was used as one group, and each group was used for each month twice a day for one month in Examples and Comparative Examples. The state of pigmentation of the skin after one month was observed and compared with that before use. .
The state of pigmentation was evaluated according to the criteria shown in Table 6,
The average value of 20 persons was calculated.
【表6】 [Table 6]
【0040】肌荒れ及び色素沈着症状の改善効果につい
て、使用試験の結果を表7にまとめて示した。表7よ
り、本発明の実施例使用群では、1カ月間の使用により
肌荒れ症状がほぼ健康な皮膚状態まで改善されており、
また色素沈着症状も著しく改善されたことが示される。
これに対し、リポ酸類或いは抗酸化性ビタミン類のいず
れかのみを含有する比較例使用群では、肌荒れ症状,色
素沈着症状ともに改善傾向は認められるものの、その程
度は実施例使用群に比べ有意に小さかった。Table 7 summarizes the results of use tests on the effects of improving skin roughness and pigmentation symptoms. From Table 7, it can be seen that in the group using the examples of the present invention, rough skin symptoms have been improved to almost healthy skin condition by use for one month,
It also shows that the pigmentation symptoms were significantly improved.
On the other hand, in the comparative example group containing only lipoic acids or antioxidant vitamins, both the rough skin condition and the pigmentation symptom tend to be improved, but the degree is significantly higher than that of the group using the example. It was small.
【表7】 [Table 7]
【0041】また、しわの発生防止効果については表8
に結果を示した。本発明の実施例塗布群では、UVAを
50週間照射した後においても、微小なしわの発生を認
めた程度であったが、比較例塗布群では、対照に比べて
しわの発生の程度は小さかったものの、中程度のしわの
発生を認めた例もあり、実施例塗布群に比べてしわの発
生防止効果は顕著に小さかった。Table 8 shows the effect of preventing the occurrence of wrinkles.
The results are shown in FIG. In the group applied with the examples of the present invention, even after irradiation with UVA for 50 weeks, the occurrence of minute wrinkles was recognized, but in the group applied with the comparative example, the occurrence of wrinkles was smaller than in the control. However, in some cases, generation of moderate wrinkles was recognized, and the effect of preventing wrinkles was remarkably small as compared with the group applied with the examples.
【表8】 [Table 8]
【0042】なお、本発明の実施例においては、3カ月
間保存後にも状態の変化を認めず、安定性についても問
題がなかった。また、上記使用試験において、皮膚刺激
性や皮膚感作性を認めたパネラーはいなかった。In the examples of the present invention, no change in state was observed even after storage for 3 months, and there was no problem in stability. In addition, in the above use test, no panelists recognized skin irritation or skin sensitization.
【0043】[0043]
【発明の効果】以上詳述したように、本発明により、優
れた活性酸素種消去作用を有し、酸化ストレスに起因す
る肌荒れやしわ,しみといった皮膚の老化症状の改善,
防止及び美白作用を有し、さらに安定性及び安全性に優
れる皮膚外用剤を提供することができた。As described above in detail, the present invention has an excellent elimination effect of reactive oxygen species and improves skin aging symptoms such as rough skin, wrinkles and spots caused by oxidative stress.
An external preparation for skin having prevention and whitening effects, and further having excellent stability and safety was provided.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 7/00 A61K 7/00 F K X ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 6 Identification number Office reference number FI Technical display location A61K 7/00 A61K 7/00 F K X
Claims (15)
種以上と、ビタミンA及びそれらの誘導体、カロテノイ
ド類、リボフラビン及びその誘導体、ビタミンB6,そ
れらの塩及び誘導体、コバラミン類、ビタミンC,その
塩及び誘導体、ビタミンE及びそれらの誘導体、ビタミ
ンK、アデノシン及びその誘導体、フラボノイド類及び
タンニン類より成る群から選択される1種又は2種以上
を含有する皮膚外用剤。1. One or two of lipoic acid, its salts and derivatives
And seeds above, vitamin A and derivatives thereof, carotenoids, riboflavin and its derivatives, vitamin B 6, their salts and derivatives, cobalamin compounds, vitamin C, salts and derivatives thereof, vitamin E and derivatives thereof, vitamin K, An external preparation for skin containing one or more selected from the group consisting of adenosine and its derivatives, flavonoids and tannins.
ルエステル,アルケニルエステル,アミド,ジヒドロリ
ポ酸及びジヒドロリポアミドより1種又は2種以上を選
択することを特徴とする、請求項1に記載の皮膚外用
剤。2. The method according to claim 1, wherein one or more of lipoic acid derivatives are selected from alkyl esters, alkenyl esters, amides, dihydrolipoic acids and dihydrolipoamides of lipoic acid. External preparation for skin.
レチノール,そのエステル,レチナール,レチノイン
酸,そのエステル,3-デヒドロレチノール,そのエステ
ル,3-デヒドロレチナール,3-デヒドロレチノイン酸,
そのエステル及びこれらと水溶性ビタミン類又はα-ヒ
ドロキシ酸との複合体より1種又は2種を選択すること
を特徴とする、請求項1又は請求項2に記載の皮膚外用
剤。3. Vitamin A and derivatives thereof,
Retinol, its ester, retinal, retinoic acid, its ester, 3-dehydroretinol, its ester, 3-dehydroretinal, 3-dehydroretinoic acid,
The external preparation for skin according to claim 1 or 2, wherein one or two types are selected from the ester and a complex of the ester and a water-soluble vitamin or α-hydroxy acid.
β-カロテン,γ-カロテン,リコペン,ルテイン,ビオ
ラキサンチン,スピリロキサンチン,スフェロイデン,
アスタキサンチンより1種又は2種以上を選択すること
を特徴とする、請求項1〜請求項3に記載の皮膚外用
剤。4. Carotenoids such as α-carotene,
β-carotene, γ-carotene, lycopene, lutein, violaxanthin, spiriroxanthin, spheroidene,
The external preparation for skin according to any one of claims 1 to 3, wherein one or more types are selected from astaxanthin.
アデニンジヌクレオチド及びフラビンモノヌクレオチド
より1種又は2種を選択することを特徴とする、請求項
1〜請求項4に記載の皮膚外用剤。5. The external preparation for skin according to claim 1, wherein one or two kinds of riboflavin derivatives are selected from flavin adenine dinucleotide and flavin mononucleotide.
リドキシン,ピリドキサール,ピリドキサミン及びこれ
らの塩より1種又は2種以上を選択することを特徴とす
る、請求項1〜請求項5に記載の皮膚外用剤。6. The skin according to claim 1, wherein one or more kinds of vitamin B 6 and salts thereof are selected from pyridoxine, pyridoxal, pyridoxamine and salts thereof. External preparation.
ン,メチルコバラミン,アデノシルコバラミン,ヒドロ
キソコバラミン及びアクアコバラミンより1種又は2種
以上を選択することを特徴とする、請求項1〜請求項6
に記載の皮膚外用剤。7. The cobalamin is selected from one or two or more of cyanocobalamin, methylcobalamin, adenosylcobalamin, hydroxocobalamin and aquacobalamin.
2. The external preparation for skin according to item 1.
アスコルビン酸,デヒドロアスコルビン酸及びこれらの
塩、アスコルビン酸リン酸エステル,ホスファチジルア
スコルビン酸及びこれらの塩、及びアスコルビン酸,デ
ヒドロアスコルビン酸とトコフェロール,アスタキサン
チンとの複合体より1種又は2種以上を選択することを
特徴とする、請求項1〜請求項7に記載の皮膚外用剤。8. Vitamin C, salts and derivatives thereof,
One or more selected from ascorbic acid, dehydroascorbic acid and salts thereof, ascorbic acid phosphate, phosphatidyl ascorbic acid and salts thereof, and a complex of ascorbic acid, dehydroascorbic acid with tocopherol and astaxanthin The external preparation for skin according to claim 1, wherein:
α-トコフェロール,β-トコフェロール,γ-トコフェ
ロール,δ-トコフェロール,これらの酢酸エステル,
ニコチン酸エステル,及びα-トコフェロール,β-トコ
フェロール,γ-トコフェロール,δ-トコフェロールと
α-ヒドロキシ酸との複合体より1種又は2種以上を選
択することを特徴とする、請求項1〜請求項8に記載の
皮膚外用剤。9. As vitamin E and derivatives thereof,
α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, their acetates,
The nicotinic acid ester and at least one selected from the group consisting of α-tocopherol, β-tocopherol, γ-tocopherol, a complex of δ-tocopherol and α-hydroxy acid, characterized in that they are selected from the group consisting of: Item 9. An external preparation for skin according to item 8.
ナキノン及びメナジオンより1種又は2種以上を選択す
ることを特徴とする、請求項1〜請求項9に記載の皮膚
外用剤。10. The external preparation for skin according to claim 1, wherein one or more kinds of vitamin K are selected from phylloquinone, menaquinone and menadione.
ルチオアデノシン,アデノシン一リン酸,環状アデノシ
ン一リン酸,アデノシン二リン酸及びアデノシン三リン
酸より1種又は2種以上を選択することを特徴とする、
請求項1〜請求項10に記載の皮膚外用剤。11. A method for selecting one or more of adenosine derivatives from 5′-methylthioadenosine, adenosine monophosphate, cyclic adenosine monophosphate, adenosine diphosphate and adenosine triphosphate. Do
The external preparation for skin according to claim 1.
ピカテキン,エリオジクチオール,エリオジクチン,ク
ウェルセチン,ヘスペリジン,ヘスペリチン及びルチン
より1種又は2種以上を選択することを特徴とする、請
求項1〜請求項11に記載の皮膚外用剤。12. The method according to claim 1, wherein one or more flavonoids are selected from catechin, epicatechin, eriodictyol, eriodictin, quercetin, hesperidin, hesperitin and rutin. 2. The external preparation for skin according to item 1.
及び茶タンニンより1種又は2種以上を選択することを
特徴とする、請求項1〜請求項12に記載の皮膚外用
剤。13. The external preparation for skin according to claim 1, wherein one or more tannins are selected from hamameli tannin and tea tannin.
2種以上と、ビタミンA及びそれらの誘導体、カロテノ
イド類、リボフラビン及びその誘導体、ビタミンB6,
それらの塩及び誘導体、コバラミン類、ビタミンC,そ
の塩及び誘導体、ビタミンE及びそれらの誘導体、ビタ
ミンK、アデノシン及びその誘導体、フラボノイド類及
びタンニン類より成る群から選択される1種又は2種以
上の配合量が、それぞれ0.01〜10重量%であるこ
とを特徴とする、請求項1〜請求項13に記載の皮膚外
用剤。14. One or more of lipoic acid, salts and derivatives thereof, vitamin A and derivatives thereof, carotenoids, riboflavin and derivatives thereof, vitamin B 6 ,
One or more selected from the group consisting of salts and derivatives thereof, cobalamin, vitamin C, salts and derivatives thereof, vitamin E and derivatives thereof, vitamin K, adenosine and derivatives thereof, flavonoids and tannins The external preparation for skin according to any one of claims 1 to 13, wherein the content of each is 0.01 to 10% by weight.
とを特徴とする、請求項1〜請求項14に記載の皮膚外
用剤。15. The external preparation for skin according to claim 1, wherein the external preparation for skin is a cosmetic for skin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18132196A JPH107541A (en) | 1996-06-20 | 1996-06-20 | Skin lotion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18132196A JPH107541A (en) | 1996-06-20 | 1996-06-20 | Skin lotion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH107541A true JPH107541A (en) | 1998-01-13 |
Family
ID=16098646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP18132196A Pending JPH107541A (en) | 1996-06-20 | 1996-06-20 | Skin lotion |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH107541A (en) |
Cited By (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000319154A (en) * | 1999-05-06 | 2000-11-21 | Nippon Menaade Keshohin Kk | Phototoxicity inhibitor |
| JP2000319159A (en) * | 1999-05-10 | 2000-11-21 | Nonogawa Shoji Kk | External preparation for skin |
| JP2001048773A (en) * | 1999-08-10 | 2001-02-20 | Naris Cosmetics Co Ltd | Cosmetic |
| JP2001158739A (en) * | 1999-09-21 | 2001-06-12 | Kyowa Hakko Kogyo Co Ltd | Composition containing proanthocyanidin and vitamin B6 derivative or salt thereof |
| JP2002506804A (en) * | 1998-03-16 | 2002-03-05 | ザ、プロクター、エンド、ギャンブル、カンパニー | Skin care composition |
| JP2002138013A (en) * | 2000-10-27 | 2002-05-14 | Pias Arise Kk | Hne-and-acrolein formation inhibiting and hne-and- acrolein decomposition promoting agent, and skin aging care preparation for external use |
| JP2002161031A (en) * | 2000-11-27 | 2002-06-04 | Noevir Co Ltd | Skin care preparation |
| WO2002072041A1 (en) * | 2001-03-13 | 2002-09-19 | Shiseido Company, Ltd. | Cosmetics and treatment method for promoting maturation of cornified envelopes |
| JP2003055188A (en) * | 2001-08-20 | 2003-02-26 | Fuji Chem Ind Co Ltd | Skin care preparation, cosmetic and food for preventing wrinkle formation |
| US6645514B1 (en) | 2002-12-19 | 2003-11-11 | Access Business Group International, Llc | Increasing skin cell renewal with water-soluble Vitamin E |
| WO2003097072A1 (en) * | 2002-05-20 | 2003-11-27 | Otsuka Pharmaceutical Co., Ltd. | Chloasma amelioration composition and dullness amelioration composition |
| WO2003086329A3 (en) * | 2002-04-09 | 2003-12-11 | Boots Co Plc | Skincare compositions comprising anti-oxidant agents |
| US6685970B1 (en) * | 1999-09-21 | 2004-02-03 | Kyowa Hakko Kogyo Co., Ltd. | Compositions containing proanthocyanidin and a vitamin B6 derivative or a salt thereof |
| JP2004091397A (en) * | 2002-08-30 | 2004-03-25 | Fancl Corp | A composition for preventing skin aging that prevents, prevents and improves flattening of the epidermis |
| WO2004043422A1 (en) * | 2002-11-13 | 2004-05-27 | Unilever Plc | Improved cosmetic composition |
| FR2847470A1 (en) * | 2002-11-26 | 2004-05-28 | Oreal | Composition useful for reducing wrinkles, relaxing the features and/or decontracting the skin comprises adenosine, a magnesium salt and a potassium salt |
| JP2004189663A (en) * | 2002-12-11 | 2004-07-08 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
| EP1508328A1 (en) * | 2003-08-22 | 2005-02-23 | L'oreal | Composition against the degradation of fibres of collagen induced in condition of natural solar exposure |
| JP2005119990A (en) * | 2003-10-15 | 2005-05-12 | Kose Corp | External preparation for skin |
| WO2006033343A1 (en) * | 2004-09-22 | 2006-03-30 | Otsuka Pharmaceutical Co., Ltd. | Composition for prevention or alleviation of pigmentation |
| JP2007513994A (en) * | 2004-08-18 | 2007-05-31 | アクヴァノヴァ・ジャーマン・ソリュービリセイト・テクノロジーズ・(アーゲーテー)・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Lipoic acid concentrate |
| JP2007145794A (en) * | 2005-11-06 | 2007-06-14 | Bhn Kk | Composition for ameliorating and/or preventing skin disorder |
| WO2007108438A1 (en) * | 2006-03-20 | 2007-09-27 | Rohto Pharmaceutical Co., Ltd. | External composition for promoting of glutathione production and relevant method |
| JP2007269672A (en) * | 2006-03-30 | 2007-10-18 | Kose Corp | Topical skin preparation |
| JP2007284430A (en) * | 2006-03-20 | 2007-11-01 | Rohto Pharmaceut Co Ltd | Glutathione production promoting agent |
| JP2009108019A (en) * | 2007-10-30 | 2009-05-21 | Bhn Kk | External preparation for skin for enhancing ultraviolet resistivity |
| FR2940907A1 (en) * | 2009-01-15 | 2010-07-16 | Oreal | COSMETIC OR DERMATOLOGICAL COMPOSITION, COMPRISING A RETINOID, A NON-PHOSPHATE COMPOUND BASED ON ADENOSINE AND A SEMI-CRYSTALLINE POLYMER |
| CN103550104A (en) * | 2013-11-08 | 2014-02-05 | 广州栋方日化有限公司 | Anti-aging preparation and cosmetic |
| WO2016170990A1 (en) * | 2015-04-18 | 2016-10-27 | ジェイオーコスメティックス株式会社 | Tyrosinase activity inhibitor and external preparation for skin |
| US9522109B2 (en) | 2011-02-14 | 2016-12-20 | J-Oil Mills, Inc. | Skin collagen enhancing agent |
| JP2018131405A (en) * | 2017-02-15 | 2018-08-23 | 株式会社ファンケル | Kallikrein 7 production-promoting composition |
| KR20190106421A (en) * | 2018-03-09 | 2019-09-18 | 김주호 | Two-layer Multi-vitaminSerum Cosmetic Composition comprising High content of L-Ascorbic Acid |
| WO2020067663A1 (en) * | 2018-09-28 | 2020-04-02 | 주식회사 엘지생활건강 | Composition for promoting skin turnover and melanin excretion |
| JP2021524495A (en) * | 2018-07-10 | 2021-09-13 | ヌチド リミテッド | A composition that protects cells from oxidative and mitochondrial stress |
| KR102379987B1 (en) * | 2021-08-16 | 2022-03-30 | (주)나우코스 | Cosmetic composition comprising vitamin e derivatives and extract of mascut bailey a for improving skin elasticity and dermal density |
| WO2025110565A1 (en) * | 2023-11-21 | 2025-05-30 | 주식회사 엘지생활건강 | Composition for enhancing skin elasticity or alleviating skin wrinkles |
-
1996
- 1996-06-20 JP JP18132196A patent/JPH107541A/en active Pending
Cited By (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002506804A (en) * | 1998-03-16 | 2002-03-05 | ザ、プロクター、エンド、ギャンブル、カンパニー | Skin care composition |
| JP2000319154A (en) * | 1999-05-06 | 2000-11-21 | Nippon Menaade Keshohin Kk | Phototoxicity inhibitor |
| JP2000319159A (en) * | 1999-05-10 | 2000-11-21 | Nonogawa Shoji Kk | External preparation for skin |
| JP2001048773A (en) * | 1999-08-10 | 2001-02-20 | Naris Cosmetics Co Ltd | Cosmetic |
| US6685970B1 (en) * | 1999-09-21 | 2004-02-03 | Kyowa Hakko Kogyo Co., Ltd. | Compositions containing proanthocyanidin and a vitamin B6 derivative or a salt thereof |
| JP2001158739A (en) * | 1999-09-21 | 2001-06-12 | Kyowa Hakko Kogyo Co Ltd | Composition containing proanthocyanidin and vitamin B6 derivative or salt thereof |
| JP2002138013A (en) * | 2000-10-27 | 2002-05-14 | Pias Arise Kk | Hne-and-acrolein formation inhibiting and hne-and- acrolein decomposition promoting agent, and skin aging care preparation for external use |
| JP2002161031A (en) * | 2000-11-27 | 2002-06-04 | Noevir Co Ltd | Skin care preparation |
| WO2002072041A1 (en) * | 2001-03-13 | 2002-09-19 | Shiseido Company, Ltd. | Cosmetics and treatment method for promoting maturation of cornified envelopes |
| JP2003055188A (en) * | 2001-08-20 | 2003-02-26 | Fuji Chem Ind Co Ltd | Skin care preparation, cosmetic and food for preventing wrinkle formation |
| WO2003086329A3 (en) * | 2002-04-09 | 2003-12-11 | Boots Co Plc | Skincare compositions comprising anti-oxidant agents |
| WO2003097072A1 (en) * | 2002-05-20 | 2003-11-27 | Otsuka Pharmaceutical Co., Ltd. | Chloasma amelioration composition and dullness amelioration composition |
| AU2003234818B8 (en) * | 2002-05-20 | 2009-03-26 | Otsuka Pharmaceutical Co., Ltd. | Chloasma amelioration composition and dullness amelioration composition |
| EP1512405A4 (en) * | 2002-05-20 | 2009-11-18 | Otsuka Pharma Co Ltd | CHLOASMA TREATMENT COMPOSITION AND MATITIS TREATMENT COMPOSITION |
| AU2003234818B2 (en) * | 2002-05-20 | 2009-03-12 | Otsuka Pharmaceutical Co., Ltd. | Chloasma amelioration composition and dullness amelioration composition |
| KR100948684B1 (en) * | 2002-05-20 | 2010-03-18 | 오츠카 세이야쿠 가부시키가이샤 | Composition for improving blemishes and compositions for improving blemishes |
| US7994153B2 (en) | 2002-05-20 | 2011-08-09 | Otsuka Pharmaceutical Co., Ltd. | Chloasma amelioration composition and dullness amelioration composition |
| EP2517712A1 (en) * | 2002-05-20 | 2012-10-31 | Otsuka Pharmaceutical Co., Ltd. | Composition for improving melasma and composition for reducing skin dullness |
| JP2004091397A (en) * | 2002-08-30 | 2004-03-25 | Fancl Corp | A composition for preventing skin aging that prevents, prevents and improves flattening of the epidermis |
| WO2004043422A1 (en) * | 2002-11-13 | 2004-05-27 | Unilever Plc | Improved cosmetic composition |
| EP1428522A1 (en) * | 2002-11-26 | 2004-06-16 | L'oreal | Cosmetic composition comprising adenosine and magnesium or potassium salts |
| FR2847470A1 (en) * | 2002-11-26 | 2004-05-28 | Oreal | Composition useful for reducing wrinkles, relaxing the features and/or decontracting the skin comprises adenosine, a magnesium salt and a potassium salt |
| JP2004189663A (en) * | 2002-12-11 | 2004-07-08 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
| US6645514B1 (en) | 2002-12-19 | 2003-11-11 | Access Business Group International, Llc | Increasing skin cell renewal with water-soluble Vitamin E |
| EP1508328A1 (en) * | 2003-08-22 | 2005-02-23 | L'oreal | Composition against the degradation of fibres of collagen induced in condition of natural solar exposure |
| JP2005119990A (en) * | 2003-10-15 | 2005-05-12 | Kose Corp | External preparation for skin |
| JP2007513994A (en) * | 2004-08-18 | 2007-05-31 | アクヴァノヴァ・ジャーマン・ソリュービリセイト・テクノロジーズ・(アーゲーテー)・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Lipoic acid concentrate |
| WO2006033343A1 (en) * | 2004-09-22 | 2006-03-30 | Otsuka Pharmaceutical Co., Ltd. | Composition for prevention or alleviation of pigmentation |
| JP2007145794A (en) * | 2005-11-06 | 2007-06-14 | Bhn Kk | Composition for ameliorating and/or preventing skin disorder |
| JP2007284430A (en) * | 2006-03-20 | 2007-11-01 | Rohto Pharmaceut Co Ltd | Glutathione production promoting agent |
| WO2007108438A1 (en) * | 2006-03-20 | 2007-09-27 | Rohto Pharmaceutical Co., Ltd. | External composition for promoting of glutathione production and relevant method |
| JP2007269672A (en) * | 2006-03-30 | 2007-10-18 | Kose Corp | Topical skin preparation |
| JP2009108019A (en) * | 2007-10-30 | 2009-05-21 | Bhn Kk | External preparation for skin for enhancing ultraviolet resistivity |
| FR2940907A1 (en) * | 2009-01-15 | 2010-07-16 | Oreal | COSMETIC OR DERMATOLOGICAL COMPOSITION, COMPRISING A RETINOID, A NON-PHOSPHATE COMPOUND BASED ON ADENOSINE AND A SEMI-CRYSTALLINE POLYMER |
| EP2208510A1 (en) | 2009-01-15 | 2010-07-21 | L'oreal | Cosmetic or dermatological composition comprising a retinoid, a non-phosphated compound based on adenosine and a semi-crystalline polymer |
| JP2010163434A (en) * | 2009-01-15 | 2010-07-29 | L'oreal Sa | Cosmetic or dermatological composition containing retinoid, adenosine-based non-phosphated compound and semi-crystalline polymer |
| US9522109B2 (en) | 2011-02-14 | 2016-12-20 | J-Oil Mills, Inc. | Skin collagen enhancing agent |
| CN103550104A (en) * | 2013-11-08 | 2014-02-05 | 广州栋方日化有限公司 | Anti-aging preparation and cosmetic |
| WO2016170990A1 (en) * | 2015-04-18 | 2016-10-27 | ジェイオーコスメティックス株式会社 | Tyrosinase activity inhibitor and external preparation for skin |
| US10632089B2 (en) | 2015-04-18 | 2020-04-28 | Jo Cosmetics Co., Ltd. | Tyrosinase activity inhibitor and external preparation for skin |
| JP2018131405A (en) * | 2017-02-15 | 2018-08-23 | 株式会社ファンケル | Kallikrein 7 production-promoting composition |
| KR20190106421A (en) * | 2018-03-09 | 2019-09-18 | 김주호 | Two-layer Multi-vitaminSerum Cosmetic Composition comprising High content of L-Ascorbic Acid |
| JP2021524495A (en) * | 2018-07-10 | 2021-09-13 | ヌチド リミテッド | A composition that protects cells from oxidative and mitochondrial stress |
| WO2020067663A1 (en) * | 2018-09-28 | 2020-04-02 | 주식회사 엘지생활건강 | Composition for promoting skin turnover and melanin excretion |
| KR102379987B1 (en) * | 2021-08-16 | 2022-03-30 | (주)나우코스 | Cosmetic composition comprising vitamin e derivatives and extract of mascut bailey a for improving skin elasticity and dermal density |
| WO2025110565A1 (en) * | 2023-11-21 | 2025-05-30 | 주식회사 엘지생활건강 | Composition for enhancing skin elasticity or alleviating skin wrinkles |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH107541A (en) | Skin lotion | |
| KR100309399B1 (en) | Preparation for epidermis | |
| EP0945128B1 (en) | Use of flavones, flavanones, or flavonoides for the protection of ascorbic acid and/or ascorbylbonds against oxidation | |
| US5972993A (en) | Composition and method for treating rosacea and sensitive skin with free radical scavengers | |
| AU2999400A (en) | Natural antioxidant compositions, method for obtaining same and cosmetic, pharmaceutical and nutritional formulations thereof | |
| KR20200056210A (en) | Non-aqueous oil balm type cosmetics composition | |
| JPH0899820A (en) | Skin external agent | |
| JP2000327550A (en) | Skin preparation for external use | |
| JPH07101844A (en) | Multilayered emulsion | |
| JP2578394B2 (en) | Whitening agent | |
| JP2663136B2 (en) | Whitening cosmetics | |
| JP2001072571A (en) | Skin preparation for external use | |
| KR101072198B1 (en) | Cosmetic composition for skin whitening | |
| EP1000603A1 (en) | Use of surface-active citric acid esters for stabilizing flavones, flavanones or flavonoids, and synergistic mixtures, cosmetic and dermatological preparations containing them | |
| KR20210158214A (en) | Ascorbyl Tetraisopalmitate-solubilization ferrocene nanocapsule composition having improved stability, and method for preparing the same, and cosmetic composition containing the same | |
| JPH05201847A (en) | Skin-beautifying cosmetic | |
| JPS6256411A (en) | Beautifying agent | |
| JP3940633B2 (en) | Topical skin preparation | |
| JP2004002219A (en) | External preparation for skin | |
| JPS6324968B2 (en) | ||
| EP0998898B1 (en) | Use of alkylglycosides for stabilizing of flavones, flavanones or flavonoids, and synergistic mixtures, cosmetic and dermatological preparations containing them | |
| EP0995422A1 (en) | Use of nitrilotriacetic acid for stabilizing of flavones, flavanones or flavonoids, and synergistic mixtures, cosmetic and dermatological preparations containing them | |
| JPH0692833A (en) | Skin external agent | |
| JPH0812532A (en) | Hair restorer | |
| JP2003321463A (en) | Skin care preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Effective date: 20040204 Free format text: JAPANESE INTERMEDIATE CODE: A131 |
|
| RD02 | Notification of acceptance of power of attorney |
Effective date: 20040220 Free format text: JAPANESE INTERMEDIATE CODE: A7422 |
|
| A521 | Written amendment |
Effective date: 20040220 Free format text: JAPANESE INTERMEDIATE CODE: A821 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040405 |
|
| A02 | Decision of refusal |
Effective date: 20040518 Free format text: JAPANESE INTERMEDIATE CODE: A02 |